Process for preparing micronized polypeptide drugs

• US 5,354,562 A
• Filed: 02/16/1993
• Issued: 10/11/1994
• Est. Priority Date: 01/21/1992
• Status: Expired due to Fees

• Current Assignee: SRI International, Inc.
• Original Assignee: SRI International, Inc.
• Inventors: Ip, Anna, Whitham, Clyde L., Platz, Robert M.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Benston, Jr., William E.
• Application Number:
  US08/017,540
• Time in Patent Office: 602 Days
• Field of Search: 424/489, 424/473.46, 514/808
• US Class Current: 424/489
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51

Abstract

Solid particle aerosol formulations of polypeptide drugs are made by lyophilizing solutions of the drugs which contain milling stabilizers that inhibit degradation of the drug during subsequent milling. The lyophilized drug is milled in fluid energy mills that have been fitted with abrasion-resistant materials and which use pure nitrogen that has been filtered to eliminate particles of greater than 0.1 μm to transport the drug. The use of (a) milling stabilizers in the solution and (b) abrasion-resistant fluid energy mills that use pure filtered nitrogen in the milling step reduce insoluble contaminants and inactive fractions in the milled product.

Claims

1. In a process for preparing a micronized polypeptide drug comprising lyophilizing a solution of the drug in a solvent and milling the lyophilized drug in a fluid energy mill using a pressurized gas to form a powder, the improvement comprising using a pure inert gas filtered to remove particles greater than about 0.1 μ

m and the improvement wherein the parts of the mill that are contacted by the pressurized gas in which the polypeptide drug is being carried are not substantially abraded by said drug-carrying gas whereby the insoluble contaminants in the micronized polypeptide drug comprise less than 2% by weight of the polypeptide drug.

4. The process of claim 1 wherein the pressure of the nitrogen is in the range of 10 to 120 psig.

5. The process of claim 4 wherein the source of the nitrogen is liquid nitrogen.

6. The process of claim 1 wherein the particle size of the micronized polypeptide drug is in the range of about 0.5 to about 15 μ

m.

7. The process of claim 1 wherein the solvent is water.

8. The process of claim 1 wherein the micronized polypeptide drug is suitable for administration as a solid particle aerosol.

2. The process of claim i wherein the polypeptide drug is labile under the milling conditions and the lyophilized drug contains a milling stabilizer.

3. The process of claim 2 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone, or mixtures thereof.

9. In a process for preparing a micronized polypeptide drug comprising lyophilizing a solution of the drug in a solvent and milling the lyophilized drug in a fluid energy mill using a pressurized gas to form a powder, the improvement comprising using a pure inert gas filtered to remove particles greater than about 0.1 μ

m and the improvement wherein the parts of the mill that are contacted by the pressurized gas in which the polypeptide drug is being carried are not substantially abraded by said drug-carrying gas whereby at least 85% of the polypeptide drug is in active form.

10. The process of claim 9 wherein the polypeptide drug is labile under the milling conditions and the lyophilized drug contains a milling stabilizer.

11. The process of claim 10 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone or mixtures thereof.

12. The process of claim 9 wherein the pressure of the nitrogen is in the range of 10 to 120 psig.

13. The process of claim 9 wherein the pressurized gas is nitrogen and the source of the nitrogen is liquid nitrogen.

14. The process of claim 9 wherein the particle size of the micronized polypeptide drug is in the range of about 0.5 to about 15 μ

m.

15. The process of claim 9 wherein the solvent is water.

16. The process of claim 9 wherein the micronized polypeptide drug is suitable for administration as a solid particle aerosol.